Last updated: April 9, 2025
Sponsor: Chinese University of Hong Kong
Overall Status: Active - Recruiting
Phase
4
Condition
Musculoskeletal Diseases
Treatment
2% Xylocaine with adrenaline 1:200,000
0.5% Levobupivacaine
Clinical Study ID
NCT04397484
2020.127-T
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
American Society of Anesthesiologists (ASA) physical status I-III
adult and scheduled to undergo elective forefoot surgery under regional anaesthesia
Exclusion
Exclusion Criteria:
patient refusal
ASA physical status > III
pregnancy
neuromuscular disorder
prior surgery in the popliteal fossa
coagulopathy
allergy to local anaesthetic drugs
skin infection at the site of needle insertion
Study Design
Total Participants: 40
Treatment Group(s): 2
Primary Treatment: 2% Xylocaine with adrenaline 1:200,000
Phase: 4
Study Start date:
September 20, 2023
Estimated Completion Date:
September 30, 2026
Study Description
Connect with a study center
Prince of Wales Hospital
Shatin, New Territories
Hong KongActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.